Articles by Louis Garguilo

  1. Nano Aids Pharma In The Business Of Delivering Chemo 1/1/2016

    An exclusive interview with the CTO of Sonrgy, Inc., a nanotechnology drug-delivery startup, who says, “Pharma is actively looking at enhancing their existing line of compounds, and embracing nanomedicine as a part of that.”

  2. In 2016, Can Outsourcing Relationships Survive The Biopharma Life Cycle? 12/1/2015

    New concepts for outsourcing must include some form of win-win even when economic, political, business, and product life cycles are at varying stages. 

  3. U.S. Biotech Meets China Capital: The Next Great Partnership? 10/1/2015

    Ambrx Inc., a quintessential American start-up in the emerging biotech cluster of San Diego, founded on revolutionary science spun out of The Scripps Research Institute, was looking for its next round of investment.

  4. A Bayer VP defines what innovation means at this Big Pharma 8/1/2015

    Among her many positive attributes, Dr. Monika Lessl is a good sport. I know because she graciously accepted to enter – at least for the duration of our interview – my neurosis regarding the word “innovation.”

  5. Can Nano Bring Us Back From Personalized To Mass Medicine? 8/1/2015

    How big can a singular change in perspective be? As big as a Copernican Revolution, you might say. Or more precisely, perhaps, how small can it be? If it’s the fundamental change that creates a metatheory moving biology to physics, it can be as small as building particles — or deconstructing them — atom-by-atom to bring new drugs to mankind. This is the big and small of nanomedicine (nano).

  6. Regeneron: A Biotech With Commercial Confidence From The First Compound 7/1/2015

    In 2001, members of a small biotech from the New York City area traveled to the state capital, Albany, to discuss accessing the state’s new Biotechnology Industry Growth Fund. An economic development official responsible for a portion of that fund met with them but came away skeptical.

  7. Samsung BioLogics: How To Build A CMO Business 6/26/2015

    In this exclusive interview with Outsourced Pharma, Tae Han Kim, PhD, president and CEO of Samsung BioLogics, shares his story of how he selected the biologics contract-manufacturing industry, the building of his business, and his first customers.

  8. At Navidea, A Scientific Advisory Board Points To New Directions 3/31/2015

    Until recently, Navidea Biopharmaceuticals (NYSE: NAVB) described itself as a leader in precision diagnostics that identify the presence and status of diseases. It focused on the development and commercialization of precision diagnostic agents for conditions such as cancer, dementia, and movement disorders.

  9. Harmonized Post-Approval Changes: A Vaccine For Global Drug Shortages 3/30/2015

    It’s true,” confirms Anders Vinther, chief quality officer at Sanofi Pasteur and a long-time chairman at Parenteral Drug Association (PDA), “global regulatory agencies have only now started to address the subject of harmonizing global post-approval change applications for drugs.”

  10. “Phase-Appropriate” Drug Development The New “Time And Place” 2/28/2015

    Parents today still caution children with the phrase, “Everything in its time and place.” For me, it just took “the look” for my parents to convey: This wasn’t the right time or place.